114 related articles for article (PubMed ID: 16865780)
1. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
3. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Xu P; Zhang XG; Li YM; Yu CH; Xu L; Xu GY
J Zhejiang Univ Sci B; 2006 Aug; 7(8):627-33. PubMed ID: 16845716
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats.
Qin Y; Tian YP
Lipids Health Dis; 2010 Jul; 9():78. PubMed ID: 20653983
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
Hardwick RN; Fisher CD; Street SM; Canet MJ; Cherrington NJ
Drug Metab Dispos; 2012 Mar; 40(3):450-60. PubMed ID: 22112382
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.
Yang SJ; Choi JM; Chae SW; Kim WJ; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW; Park CY
PLoS One; 2011 Feb; 6(2):e17057. PubMed ID: 21373642
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe treatment reduces oxidized low-density lipoprotein in biliary cirrhotic rats.
Chang CC; Huang HC; Hsu SJ; Pun CK; Chuang CL; Hou MC; Lee FY
J Chin Med Assoc; 2024 May; 87(5):463-470. PubMed ID: 38380910
[TBL] [Abstract][Full Text] [Related]
8. Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.
Yang SJ; Choi JM; Chang E; Park SW; Park CY
PLoS One; 2014; 9(8):e105456. PubMed ID: 25133775
[TBL] [Abstract][Full Text] [Related]
9. Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction.
Keingeski MB; Longo L; Brum da Silva Nunes V; Figueiró F; Dallemole DR; Pohlmann AR; Vier Schmitz TM; da Costa Lopez PL; Álvares-da-Silva MR; Uribe-Cruz C
Metab Syndr Relat Disord; 2024 Jun; 22(5):394-401. PubMed ID: 38498801
[No Abstract] [Full Text] [Related]
10. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters.
Bhathena J; Martoni C; Kulamarva A; Tomaro-Duchesneau C; Malhotra M; Paul A; Urbanska AM; Prakash S
PLoS One; 2013; 8(3):e58394. PubMed ID: 23554890
[TBL] [Abstract][Full Text] [Related]
11. Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Corey KE; Chalasani N
Hepatology; 2011 Nov; 54(5):1503-5. PubMed ID: 21953015
[No Abstract] [Full Text] [Related]
12. The α-tocopherol status and expression of α-tocopherol-related proteins in methionine-choline deficient rats treated with vitamin E.
Miyazaki H; Takitani K; Koh M; Yoden A; Tamai H
J Clin Biochem Nutr; 2014 May; 54(3):190-7. PubMed ID: 24895482
[TBL] [Abstract][Full Text] [Related]
13. The Eeffect of Metformin Combined with Calcium-Vitamin D
Shojaei Zarghani S; Abbaszadeh S; Alizadeh M; Rameshrad M; Garjani A; Soraya H
Adv Pharm Bull; 2018 Mar; 8(1):97-105. PubMed ID: 29670844
[No Abstract] [Full Text] [Related]
14. A systems biology approach to identify effective cocktail drugs.
Wu Z; Zhao XM; Chen L
BMC Syst Biol; 2010 Sep; 4 Suppl 2(Suppl 2):S7. PubMed ID: 20840734
[TBL] [Abstract][Full Text] [Related]
15. Multiparticulate Systems of Ezetimibe Micellar System and Atorvastatin Solid Dispersion Efficacy of Low-Dose Ezetimibe/Atorvastatin on High-Fat Diet-Induced Hyperlipidemia and Hepatic Steatosis in Diabetic Rats.
Torrado-Salmerón C; Guarnizo-Herrero V; Henriques J; Seiça R; Sena CM; Torrado-Santiago S
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33804727
[TBL] [Abstract][Full Text] [Related]
16. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease.
Vachliotis ID; Polyzos SA
Curr Obes Rep; 2023 Sep; 12(3):191-206. PubMed ID: 37407724
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes.
Li J; Shen X
Diabetol Metab Syndr; 2019; 11():35. PubMed ID: 31073335
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.
Singh S; Osna NA; Kharbanda KK
World J Gastroenterol; 2017 Sep; 23(36):6549-6570. PubMed ID: 29085205
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.
Fraunberger P; Gröne E; Gröne HJ; Drexel H; Walli AK
J Inflamm (Lond); 2017; 14():3. PubMed ID: 28167864
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
van der Veen JN; Lingrell S; Gao X; Takawale A; Kassiri Z; Vance DE; Jacobs RL
J Lipid Res; 2017 Apr; 58(4):656-667. PubMed ID: 28159867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
